1.Hepatocellular carcinoma composed of two different histologic types: imaging features on gadoxetic acid-enhanced liver MRI.
Seung Hyun KIM ; Woo Kyoung JEONG ; Yongsoo KIM ; Min Yeong KIM ; Jinoo KIM ; Ju Yeon PYO ; Young Ha OH
Clinical and Molecular Hepatology 2013;19(1):92-96
No abstract available.
Antigens, CD34/metabolism
;
Carcinoma, Hepatocellular/pathology/*radiography
;
Contrast Media/chemistry/diagnostic use
;
Gadolinium DTPA/chemistry/*diagnostic use
;
Humans
;
Immunohistochemistry
;
Liver Neoplasms/pathology/*radiography
;
Magnetic Resonance Imaging
;
Male
;
Middle Aged
;
Tomography, X-Ray Computed
2.Visualization of Tumor Angiogenesis Using MR Imaging Contrast Agent Gd-DTPA-anti-VEGF Receptor 2 Antibody Conjugate in a Mouse Tumor Model.
Hong Young JUN ; Hong Hua YIN ; Sun Hee KIM ; Seong Hoon PARK ; Hun Soo KIM ; Kwon Ha YOON
Korean Journal of Radiology 2010;11(4):449-456
OBJECTIVE: To visualize tumor angiogenesis using the MRI contrast agent, Gd-DTPA-anti-VEGF receptor 2 antibody conjugate, with a 4.7-Tesla MRI instrument in a mouse model. MATERIALS AND METHODS: We designed a tumor angiogenesis-targeting T1 contrast agent that was prepared by the bioconjugation of gadolinium diethylenetriaminepentaacetic acid (Gd-DTPA) and an anti-vascular endothelial growth factor receptor-2 (VEGFR2) antibody. The specific binding of the agent complex to cells that express VEGFR2 was examined in cultured murine endothelial cells (MS-1 cells) with a 4.7-Tesla magnetic resonance imaging scanner. Angiogenesis-specific T1 enhancement was imaged with the Gd-DTPA-anti-VEGFR2 antibody conjugate using a CT-26 adenocarcinoma tumor model in eight mice. As a control, the use of the Gd-DTPA-anti-rat immunoglobulin G (Gd-DTPA-anti-rat IgG) was imaged with a tumor model in eight mice. Statistical significance was assessed using the Mann-Whitney test. Tumor tissue was examined by immunohistochemical analysis. RESULTS: The Gd-DTPA-anti-VEGFR2 antibody conjugate showed predominant binding to cultured endothelial cells that expressed a high level of VEGFR2. Signal enhancement was approximately three-fold for in vivo T1-weighted MR imaging with the use of the Gd-DTPA-anti-VEGFR2 antibody conjugate as compared with the Gd-DTPA-rat IgG in the mouse tumor model (p < 0.05). VEGFR2 expression in CT-26 tumor vessels was demonstrated using immunohistochemical staining. CONCLUSION: MR imaging using the Gd-DTPA-anti-VEGFR2 antibody conjugate as a contrast agent is useful in visualizing noninvasively tumor angiogenesis in a murine tumor model.
Adenocarcinoma/*pathology
;
Animals
;
Colonic Neoplasms/*pathology
;
Contrast Media/chemistry/*diagnostic use
;
Gadolinium DTPA/chemistry/*diagnostic use
;
Immunoenzyme Techniques
;
Magnetic Resonance Imaging/*methods
;
Mice
;
Mice, Nude
;
Neovascularization, Pathologic/*diagnosis
;
Rats
;
Statistics, Nonparametric
;
Tumor Cells, Cultured
;
Vascular Endothelial Growth Factor Receptor-2/*antagonists & inhibitors/chemistry